Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Alka-Seltzer Plus Ad Modifications Not Sufficient, NAD Decides

This article was originally published in The Tan Sheet

Executive Summary

Bayer has assured the National Advertising Division of the Council of Better Business Bureaus it immediately discontinued certain parity claims made for Alka-Seltzer Plus Cold Medicine after NAD decided the modified advertising still was problematic.

You may also be interested in...



Regulatory News In Brief

FDA distinguishes supplements from medical foods; super fruits are not drugs, FA explains; Sunland resumes production; Bayer voluntarily nixes Alka-Seltzer claims; FDA cites inflammation as drug claim; three Florida supplement makers warned for drug claims; and FDA warns Michigan e-commerce firm on claims.

Regulatory News In Brief

FDA distinguishes supplements from medical foods; super fruits are not drugs, FA explains; Sunland resumes production; Bayer voluntarily nixes Alka-Seltzer claims; FDA cites inflammation as drug claim; three Florida supplement makers warned for drug claims; and FDA warns Michigan e-commerce firm on claims.

Alka-Seltzer Plus Cold Medicine Modified Claims Suggested By NAD

Parity claims in advertisements for Bayer Consumer Care's Alka-Seltzer Plus Cold Medicine cannot be supported by the proven safety and efficacy of the product's individual ingredients, the Council for Better Business Bureaus' National Advertising Division determines in a recent case report.

Related Content

Topics

UsernamePublicRestriction

Register

PS091087

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel